Tissue Polypeptide Antigen and Tissue Polypeptide Specific Antigen in Primary Breast Cancer. Evaluation in Serum and Tutmour Tissue

Gion, Massimo; Mione, R; Barioli, P.; Sartorello, P.; Capitanio, Giovanni

doi:10.1515/cclm.1994.32.10.779

Cited by 3 publications

(3 citation statements)

References 16 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TPA is recognised by polyclonal antisera against cytokeratins 8, 18 and 19. To enhance the sensitivity and specificity of TPA assay, a new assay is now available, which is based on the use of three monoclonal antibodies directed against cytokeratins 8, 18 and 19, allowing detection of TPM antigen (Gion et al, 1994). CYFRA 21-1 detects a fragment of cytokeratin 19 (Pujol et al, 1993).…”

mentioning

confidence: 99%

Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?

Plebani

Basso²,

Navaglia³

et al. 1995

Br J Cancer

View full text Add to dashboard Cite

Summary In this study we compared the diagnostic utility of: (1) neuron-specific enolase (NSE); (2) squamous cell carcinoma antigen (SCC); (3) carcinoembryonic antigen (CEA); and (4) cytokeratin markers (CYFRA 21-1, TPA, TPM, TPS) in patients with small-cell lung cancer (SCLC) (21 cases) and non-small-cell lung cancer (94 cases). For comparison we also studied 66 patients with benign lung diseases and nine with pleural mesothelioma. NSE levels in SCLC patients were significantly higher than those in all the other groups studied. No significant variations were found among the SCC levels in all groups. CEA levels in patients with adenocarcinoma were significantly higher than those in all other groups studied. CYFRA 21-1 serum levels significantly increased in patients with squamous cell carcinoma and mesothelioma, while TPA, TPS and TPM increased in patients with lung cancer irrespective of the histological type. In patients with SCLC, high levels of all markers except SCC were found when the disease was extensive. In patients with non-SCLC, the highest levels of all tumour markers were usually found in those with advanced disease, although CYFRA 21-1 gave a sensitivity of 44% when a specificity of 95% was fixed in stage I non-SCLC patients. An analysis of receiver operating characteristic curves revealed that the highest diagnostic accuracies in distinguishing benign from malignant lung diseases were achieved with TPM (81%), CYFRA 21-1 (72%), CEA (78%) or TPA (78%) when using cut-off values of 46 U 1-', 3.0 g 1-g', 2.0 ;g l-l and 75 U l-1' respectively. When all patients were considered, the combined evaluation of more than one marker did not significantly improve the results obtained with TPM alone. However, taking into consideration the fact that CYFRA 21-1 is the most sensitive index of early lung tumours and that its combined determination with TPM did not worsen the overall sensitivity and specificity of the latter, the combined use of these two markers may be suggested as a useful took for the diagnosis of lung tumours.

show abstract

mentioning

confidence: 99%

Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?

Plebani

Basso²,

Navaglia³

et al. 1995

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…The inverse relationships be tween TPA or TPS positivity, with either tumor grade or Ki67 were unexpected, as these markers are supposed to reflect tumor proliferation and aggressiveness [26,29,30], Our data seem to be in agreement with those reported by Gion et al [ 17], who described an inverse correlation between cell proliferation measured using the 3H-thymidinc labeling in dex and cytosolic levels of both TPA and TPS. In another study, however, the same authors failed to show any significant changes in the serum levels of these markers when related to histological type or tumor grade [31], Any way, the number of cases included in this study is too small to perform these correla tions; these findings should therefore be con firmed in wider series.…”

Section: Tumor Markers In Priman' Breast Cancermentioning

confidence: 55%

Influence of Neoadjuvant Chemotherapy on Serum Tumor Markers CA 15-3, MCA, CEA, TPS and TPA in Breast Cancer Patients with Operable Disease

Bottini¹,

Berruti

Tampellini

et al. 1997

Tumor Biol

View full text Add to dashboard Cite

Serum levels of CA 15–3, mucinous-like cancer antigen, carcinoembryonic antigen, tissue polypeptide antigen and tissue polypeptide-specific antigen (TPS) have been determined in 99 patients with T_2–4 N_0–1 M₀ breast cancer (BC) before and after primary (neoadjuvant) chemotherapy and after surgery. As a whole, no difference in marker levels was apparent according to tumor and patient characteristics, with the only exception of TPS values, which showed an inverse relationship with the histologic grade. Serum marker levels did not substantially change with respect to baseline either after chemotherapy, despite the high response rate obtained, or after surgery. These data indicate a limited contribution of the primary tumor to the serum marker levels and are consistent for the scarce usefulness of marker evaluation in BC patients with an early stage of disease. Interestingly, pretreatment elevated CA 15–3 levels were correlated with a higher recurrence rate, further supporting the prognostic significance of this tumor marker.

show abstract

“…In this optic, non-invasive liquid biopsies and the measurement of specific blood-based biomarkers represent an effective alternative parameter to monitored invasive BC patients. Cancer Antigen 15-3 (CA 15-3), carcinoembryonic antigen, tissue polypeptide antigen, tissue polypeptide-specific antigen and the soluble form of HER2 represent the most detected serum BC biomarkers [172][173][174] . Nevertheless, even if it has been demonstrated a correlation between single or combined circulating biomarker levels and recurrence incidence, many issues need to be solved [175][176][177][178] .…”

Section: Clinical Relevance Of Ctcsmentioning

confidence: 99%

Circulating tumor cells and the metastatic process: the complexity of malignancy

Raimo¹,

Santis²,

Coppola³

et al. 2018

JCMT

View full text Add to dashboard Cite

Despite improvements achieved in terms of early detection and therapeutic approach, metastatic breast cancer remains one of the principal worldwide causes of death. In recent years, due to the heterogeneous response of each patient to chemotherapy, clinical research highlights the need of a personalized approach. Circulating tumor cells (CTCs) represents a promising tool for this purpose. Unfortunately, even if their correlation with severity, outcome and metastatic nature of the tumor has been established, several issues, mainly concerning their characterization and isolation, need to be solved. In this review, latest knowledge on CTCs and metastatic process in breast cancer were analyzed, aiming to understand their clinical utility and validity for a prospective therapeutic scenario.

show abstract

Tissue Polypeptide Antigen and Tissue Polypeptide Specific Antigen in Primary Breast Cancer. Evaluation in Serum and Tutmour Tissue

Cited by 3 publications

References 16 publications

Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?

Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?

Influence of Neoadjuvant Chemotherapy on Serum Tumor Markers CA 15-3, MCA, CEA, TPS and TPA in Breast Cancer Patients with Operable Disease

Circulating tumor cells and the metastatic process: the complexity of malignancy

Contact Info

Product

Resources

About